![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MJ Marks, SF Robinson and AC Collins
Institute for Behavioral Genetics, University of Colorado, Boulder, USA.
The effects of the nicotinic agonists acetylcholine, (+)-anatox in-a, carbachol, cytisine, dimethylphenylpiperazinum, (+)-epibatidine, (-)- epibatidine, methylcarbachol, D-nicotine, L-nicotine, and tetramethylammonium on 86Rb+ efflux from mouse thalamic synaptosomes were investigated. All 11 agonists evoked a concentration-dependent stimulation of 86Rb+ efflux as well as a time- and concentration- dependent reduction of response (desensitization). The agonists varied widely in potency, efficacy and rate of desensitization. (+)- Epibatidine was the most potent agonist (EC50 = 10 nM), whereas tetramethylammonium was the least potent (EC50 = 65 microM). The agonists containing a quaternary ammonium group were generally more efficacious than the other agonists, except for both of the enantiomers of epibatidine, which stimulated 86Rb+ efflux at least as well as acetylcholine. Cytisine was the least efficacious compound tested with a maximal response approximately 10% that of (-)-epibatidine. Exposure of the thalamic synaptosomes to agonist concentrations that generally stimulated little or no efflux reduced in a concentration-dependent manner a subsequent response to 10 microM nicotine. The IC50 values for this functional blockade (desensitization) were highly correlated with the Ki values for the inhibition of [3H]nicotine binding. Furthermore, exposure of the thalamic synaptosomes to 300 nM L-nicotine reduced the responses evoked by a subsequent exposure to a stimulating concentration of all 11 agonists. The observation of desensitization by both stimulating and substimulating concentrations of each agonist is consistent with the predictions of the two-state model of Katz and Thesleff.
This article has been cited by other articles:
|
|
 |
|
  A. R. Glatt, K. Denton, and J. D. Boughter Jr Variation in Nicotine Consumption in Inbred Mice Is Not Linked to Orosensory Ability Chem Senses, September 4, 2008; (2008) bjn049v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xiao, H. Fan, J. L. Musachio, Z.-L. Wei, S. K. Chellappan, A. P. Kozikowski, and K. J. Kellar Sazetidine-A, A Novel Ligand That Desensitizes {alpha}4beta2 Nicotinic Acetylcholine Receptors without Activating Them Mol. Pharmacol., October 1, 2006; 70(4): 1454 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Fitch, Y. Xiao, K. J. Kellar, and J. W. Daly Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function PNAS, April 15, 2003; 100(8): 4909 - 4914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dobelis, M. J. Marks, P. Whiteaker, S. A. Balogh, A. C. Collins, and J. A. Stitzel A Polymorphism in the Mouse Neuronal alpha 4 Nicotinic Receptor Subunit Results in An Alteration in Receptor Function Mol. Pharmacol., August 1, 2002; 62(2): 334 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Rossi, T. Pizzorusso, V. Porciatti, L. M. Marubio, L. Maffei, and J.-P. Changeux Requirement of the nicotinic acetylcholine receptor beta 2 subunit for the anatomical and functional development of the visual system PNAS, May 3, 2001; (2001) 101120998. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. G. V. Sharples, S. Kaiser, L. Soliakov, M. J. Marks, A. C. Collins, M. Washburn, E. Wright, J. A. Spencer, T. Gallagher, P. Whiteaker, et al. UB-165: A Novel Nicotinic Agonist with Subtype Selectivity Implicates the alpha 4beta 2* Subtype in the Modulation of Dopamine Release from Rat Striatal Synaptosomes J. Neurosci., April 15, 2000; 20(8): 2783 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, M. J. Marks, and A. C. Collins Desensitization of Nicotinic Agonist-Induced [3H]gamma -Aminobutyric Acid Release from Mouse Brain Synaptosomes Is Produced by Subactivating Concentrations of Agonists J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1127 - 1134. [Abstract] [Full Text]
|
|
|
|
|
|
C. P. Fenster, T. L. Whitworth, E. B. Sheffield, M. W. Quick, and R. A. J. Lester Upregulation of Surface alpha 4beta 2 Nicotinic Receptors Is Initiated by Receptor Desensitization after Chronic Exposure to Nicotine J. Neurosci., June 15, 1999; 19(12): 4804 - 4814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Marks, P. Whiteaker, J. Calcaterra, J. A. Stitzel, A. E. Bullock, S. R. Grady, M. R. Picciotto, J.-P. Changeux, and A. C. Collins Two Pharmacologically Distinct Components of Nicotinic Receptor-Mediated Rubidium Efflux in Mouse Brain Require the beta 2 Subunit J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1090 - 1103. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Lu, S. Grady, M. J. Marks, M. Picciotto, J.-P. Changeux, and A. C. Collins Pharmacological Characterization of Nicotinic Receptor-stimulated GABA Release From Mouse Brain Synaptosomes J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 648 - 657. [Abstract] [Full Text]
|
|
|
|
|
|
P. Whiteaker, C. G. V. Sharples, and S. Wonnacott Agonist-Induced Up-Regulation of alpha 4beta 2 Nicotinic Acetylcholine Receptors in M10 Cells: Pharmacological and Spatial Definition Mol. Pharmacol., May 1, 1998; 53(5): 950 - 962. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Marks, K. W. Smith, and A. C. Collins Differential Agonist Inhibition Identifies Multiple Epibatidine Binding Sites in Mouse Brain J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 377 - 386. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. A. Penn, P. A. Riquelme, M. B. Feller, and C. J. Shatz Competition in Retinogeniculate Patterning Driven by Spontaneous Activity Science, March 27, 1998; 279(5359): 2108 - 2112. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Frazier, Y. D. Rollins, C. R. Breese, S. Leonard, R. Freedman, and T. V. Dunwiddie Acetylcholine Activates an alpha -Bungarotoxin-Sensitive Nicotinic Current in Rat Hippocampal Interneurons, But Not Pyramidal Cells J. Neurosci., February 15, 1998; 18(4): 1187 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Grady, E. U. Grun, M. J. Marks, and A. C. Collins Pharmacological Comparison of Transient and Persistent [3H]Dopamine Release from Mouse Striatal Synaptosomes and Response to Chronic L-Nicotine Treatment J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 32 - 43. [Abstract] [Full Text]
|
|
|
|
|
|
K. Fattinger, D. Verotta, and N. L. Benowitz J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1238 - 1246. [Abstract] [Full Text]
|
|
|
|
|
|
F. M. Rossi, T. Pizzorusso, V. Porciatti, L. M. Marubio, L. Maffei, and J.-P. Changeux Requirement of the nicotinic acetylcholine receptor beta 2 subunit for the anatomical and functional development of the visual system PNAS, May 22, 2001; 98(11): 6453 - 6458. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
